Notably, 79% (49 out of 60 patients with ovarian cancer) did not harbor tumor BRCA1 or BRCA2 (tBRCA) mutations, and 53% had a negative HRD status based on the assay from Myriad Genetics, but the clinical benefits of this combination were apparent regardless of tBRCA mutation or HRD status. Here, BRCA1 is linked to ovarian carcinoma.